Nurexone Biologic (Otcqb:Nrxbf) (Tsxv: Nrx) (Fse: J90)

Nurexone Biologic (Otcqb:Nrxbf) (Tsxv: Nrx) (Fse: J90) company information, Employees & Contact Information

NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

Company Details

Employees
24
Founded
-
Address
Haifa, Il
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
jobs.
HQ
Haifa
Looking for a particular Nurexone Biologic (Otcqb:Nrxbf) (Tsxv: Nrx) (Fse: J90) employee's phone or email?

Nurexone Biologic (Otcqb:nrxbf) (Tsxv: Nrx) (Fse: J90) Questions

News

NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model - GlobeNewswire

NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model GlobeNewswire

NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana - The Manila Times

NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana The Manila Times

NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard - GlobeNewswire

NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard GlobeNewswire

NurExone Invited Presenter at Precision EV Forum in Cambridge, UK - The Manila Times

NurExone Invited Presenter at Precision EV Forum in Cambridge, UK The Manila Times

ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery - GlobeNewswire

ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery GlobeNewswire

NurExone Biologic to Participate in 2022 Bio-Europe Conference - Yahoo Finance

NurExone Biologic to Participate in 2022 Bio-Europe Conference Yahoo Finance

NurExone Reports Second Quarter 2022 Financial Results and Provides Business Update - Newsfile

NurExone Reports Second Quarter 2022 Financial Results and Provides Business Update Newsfile

NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage - GlobeNewswire

NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage GlobeNewswire

NurExone Exosomes to Be Used in Cutting Edge Molecular Research at Hebrew University's Burstyn-Cohen Lab - Newsfile

NurExone Exosomes to Be Used in Cutting Edge Molecular Research at Hebrew University's Burstyn-Cohen Lab Newsfile

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma - GlobeNewswire

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma GlobeNewswire

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market - GlobeNewswire

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market GlobeNewswire

Top Nurexone Biologic (Otcqb:Nrxbf) (Tsxv: Nrx) (Fse: J90) Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant